Establishment of a mouse model of 70% lethal dose by total-body irradiation

• Published in: Laboratory animal research Vol. 32; no. 2; pp. 116 - 121
• Main Authors: Ryu, Seung-Hyun, Park, Jong-Hyung, Jeong, Eui-Suk, Choi, Soo-Young, Ham, Seung-Hoon, Park, Jin-Il, Jeon, Hee-Yeon, Kim, Jun-Young, Yoo, Ran-Ji, Lee, Yong-Jin, Woo, Sang-Keun, Choi, Yang-Kyu
• Format: Journal Article
• Language: English
• Published: England Korean Association for Laboratory Animal Science 01-06-2016; BMC; 한국실험동물학회
• Subjects: LD70/30; mice; Original; Total-body irradiation; 수의학; model; LD70/30; mice; Total-body irradiation
• ISSN: 1738-6055; 2233-7660
• DOI: 10.5625/lar.2016.32.2.116

Whereas increasing concerns about radiation exposure to nuclear disasters or side effects of anticancer radiotherapy, relatively little research for radiation damages or remedy has been done. The purpose of this study was to establish level of LD70/30 (a lethal dose for 70% of mice within 30 days) by total-body γ irradiation (TBI) in a mouse model. For this purpose, at first, 8-week-old male ICR and C57BL/6N mice from A and B companies were received high dose (10, 11, 12 Gy) TBI. After irradiation, the body weight and survival rate were monitored for 30 days consecutively. In next experiment, 5-week-old male ICR and C57BL/6N mice from B company were received same dose irradiation. Results showed that survival rate and body weight change rate in inbred C57BL/6N mice were similar between A and B company. In ICR mice, however, survival rate and body weight change rate were completely different among the companies. Significant difference of survival rate both ICR and C57BL6N mice was not observed in between 5-week-old and 8-week-old groups receiving 10 or 12 Gy TBI. Our results indicate that the strain and age of mice, and even purchasing company (especially outbred), should be matched over experimental groups in TBI experiment. Based on our results, 8-week-old male ICR mice from B company subjected to 12 Gy of TBI showed LD70/30 and suitable as a mouse model for further development of new drug using the ideal total-body irradiation model.